ALK launches neffy 2 mg in Canada after April 2026 approval

The needle-free nasal adrenaline spray targets emergency treatment of anaphylaxis in adults and children weighing at least 30 kg, expanding ALK’s neffy rollout beyond Europe.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.